European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Phase 1 dosing is expected to finish by the end of 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
Subscribe To Our Newsletter & Stay Updated